Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenQuadfi vs Menactra Immunogenicity and Safety in Individuals 2 to 55 Years
NCT04368429Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of meningococcal A conjugate vaccine in invasive meningococcal disease (IMD), sponsored by Sanofi. Started May 2020; status: completed.
02
Drugs
meningococcal A conjugate vaccine
03
Conditions
invasive meningococcal disease (IMD)
Beyond the preview
Go deeper on NCT04368429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368429.